G-Spring
G-Spring, licence 80062662: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Magnum Nutraceuticals Inc.
- NPN or DIN-HM
- 80062662
- Status
- Active licence
- Licence date
- 13 July 2015
- Revision date
- 5 January 2024
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Dose déclarée au-delà d'une limite
Vitamine D: up to 12.5 µg a day according to the dosing instructions published by Health Canada (2 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 5 µg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Conditions légales
Pueraria montana var. lobata (Willd.) Sanjappa & Pradeep: La portion journalière recommandée ne doit pas conduire à une ingestion d'isoflavones supérieure à 1 mg/kg de poids corporel (exprimés comme aglycone du composant principal). L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| L-Lysine Source : L-Lysine | 250.0 mg | Not calculated |
| 5-Oxo-L-proline, composé avec de L-arginine(1:1) Source : Arginine PCA | 250.0 mg | Not calculated |
| Vitamine D Source : Cholécalciférol | 6.25 mcg | 12.5 µg |
| Mucuna pruriens Source : Graine(s) Extract : Matériel brut sec Extraction ratio : 15.0:1.0 Dry plant equivalent : 1125.0 mg | 75.0 mg | Not calculated |
| Pueraria montana var. lobata Source : Racine Extraction ratio : 90:1 Dry plant equivalent : 2.25 g Potency : 24.75 mg Puerarin | 25.0 mg | Not calculated |
| L-théanine Source : L-Théanine | 25.0 mg | Not calculated |
| 2-(diméthylamino)éthanol Source : Bitartrate de déanol | 9.25 mg | Not calculated |
| N-[2-(5-méthoxy-1H-indol-3-yl)éthyl]acétamide Source : Mélatonine | 5.0 mg | Not calculated |
| N-[2-(5-méthoxy-1H-indol-3-yl)éthyl]acétamide Source : Animaux autre que l'humain non susceptibles à l' EST - Corps pinéal | 5.0 mg | Not calculated |
| Bacopa monnieri Source : Feuille Extract : Matériel brut sec Extraction ratio : 30.0:1.0 Dry plant equivalent : 1650.0 mg Potency : 50.0 % Bacosides A and B | 55.0 mg | Not calculated |
| Piper nigrum Source : Fruit Extract : Matériel brut sec Extraction ratio : 25.0:1.0 Dry plant equivalent : 31.25 mg Potency : 95.0 % Piperine | 1.25 mg | Not calculated |
Non-medicinal ingredients
Bleu FD&C n° 1, Dioxyde de silicium, Jaune FD&C n° 6, Gélatine, Cellulose microcristalline, Rouge FD&C No. 3
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 2.0 Capsule | 1.0 Jour(s) |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps increase the total sleep time (aspect of sleep quality) in people suffering from sleep restriction or altered sleep schedule, e.g. shift-work and jet lag. Helps to reduce the time it takes to fall asleep (sleep onset latency aspect of sleep quality) in people with delayed sleep phase disorder. Helps re-set the body's sleep-wake cycle (aspect of the circadian rhythm). Helps in the development and maintenance of bones and teeth. Helps in the absorption and use of calcium and phosphorus. Calcium intake, when combined with sufficient Vitamin D, a healthy diet and regular exercise may reduce the risk of developing osteoporosis. L-Arginine is a non-essential amino acid that is involved in protein synthesis. Source of Lysine, an essential amino acid for the maintenance of good health. Helps in collagen formation.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80062662
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2024. Photograph the packaging to check whether it has changed.
Has the product changed? Photograph the packaging.